- Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services, reporting Q1 2026 revenues of $2.90 billion, a 9.2% increase from the previous year, with a strong focus on Advanced Diagnostics and organic growth.
- In the past year, Quest Diagnostics launched its Quest AD-Detect® blood tests for Alzheimer's disease and expanded its Co-Lab Solutions with Corewell Health, contributing to double-digit revenue growth in Advanced Diagnostics.
- Key partnerships include a joint venture laboratory with Corewell Health in Michigan and services for over 200,000 patients at Fresenius dialysis centers, enhancing their market presence in critical healthcare segments.
- The ideal buyer for Quest Diagnostics includes healthcare providers and hospitals seeking reliable diagnostic solutions, as the company addresses the growing demand for diagnostic testing, particularly in non-urgent surgeries among older Americans.
Quest Diagnostics operates with a diverse departmental structure, comprising 13 distinct departments. The largest departments include Health Services with 37 employees, Community and Social Services with 34, and Operations housing 33 staff members. This distribution reflects a strong emphasis on health-related services, while also maintaining a balanced presence in support functions such as Information Technology and Sales. Overall, the workforce demonstrates a strategic alignment with the company's focus on healthcare delivery and operational efficiency.
The company maintains a widespread geographic presence across 150 locations, with notable concentrations in Covina, CA and New York, NY, each employing 10 staff members. Other significant locations include Las Vegas, NV with 8 employees and Quakertown, PA with 7. The 'Other' category accounts for 134 employees, indicating a distributed workforce across various regions. This distribution suggests a strategic approach to service delivery, enabling the company to effectively reach diverse markets while maintaining operational flexibility.
